Frances Valdes-Albini, MD
There are multiple therapeutic options in development for the treatment of patients with HER2-positive breast cancer, further adding to the regimens available, explains Frances Valdes-Albini, MD, assistant professor of clinical medicine at the University of Miami Miller School of Medicine.
State of the Science Summit™ on Breast Cancer, Albini discussed the novel treatment approaches being developed in the HER2-positive breast cancer paradigm.
In the phase III randomized SOPHIA trial, margetuximab plus chemotherapy is being compared with trastuzumab (Herceptin) plus chemotherapy in the treatment of patients with HER2-positive metastatic breast cancer (NCT02492711). The purpose of this study is to determine whether patients treated with margetuximab plus chemotherapy have longer progression-free survival (PFS) and overall survival (OS) than patients treated with trastuzumab plus chemotherapy.
... to read the full story